Leukaemia inhibitory factor abrogates Paclitaxel-induced axonal atrophy in the Wistar rat

Brain Res. 2001 Aug 24;911(2):163-7. doi: 10.1016/s0006-8993(01)02627-0.

Abstract

A prominent side effect of Paclitaxel chemotherapy is sensorimotor peripheral neuropathy. Leukaemia inhibitory factor (LIF) supports the survival and regrowth of axotomised sensory and motor neurons and we therefore investigated if systemically administered LIF abrogated Paclitaxel-induced neuropathy. We found that whereas animals administered Paclitaxel alone exhibited a significant decrease in the percentage of large myelinated axons, this reduction was prevented by the co-administration of LIF.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents, Phytogenic / pharmacology*
  • Axons / drug effects*
  • Axons / pathology
  • Calcitonin Gene-Related Peptide / metabolism
  • Cell Count
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Interactions / physiology*
  • Ganglia, Spinal / drug effects
  • Ganglia, Spinal / pathology
  • Growth Inhibitors / pharmacology*
  • Immunohistochemistry
  • Interleukin-6*
  • Leukemia Inhibitory Factor
  • Lymphokines / pharmacology*
  • Nerve Degeneration / chemically induced
  • Nerve Degeneration / drug therapy*
  • Nerve Degeneration / physiopathology
  • Neural Conduction / drug effects
  • Neural Conduction / physiology
  • Neurons, Afferent / drug effects
  • Neurons, Afferent / pathology
  • Paclitaxel / pharmacology*
  • Peripheral Nervous System Diseases / chemically induced
  • Peripheral Nervous System Diseases / drug therapy*
  • Peripheral Nervous System Diseases / physiopathology
  • Rats
  • Rats, Wistar
  • Substance P / metabolism

Substances

  • Antineoplastic Agents, Phytogenic
  • Growth Inhibitors
  • Interleukin-6
  • Leukemia Inhibitory Factor
  • Lymphokines
  • Substance P
  • Calcitonin Gene-Related Peptide
  • Paclitaxel